Biocon Q3 results: All business segments grow; EBITDA up 16%, revenue rises 7%

In the corresponding quarter last year, Biocon’s earnings included revenue from the Branded Formulations India (BFI) business, which has since been divested, along with an income of ₹350 crore from the partial divestment of BFI units by Biocon Biologics and a gain of ₹456 crore from Biocon’s stake dilution in Bicara Therapeutics.

Adjusting for these factors, Biocon’s Q3 FY25 operating revenue stood at ₹3,821 crore, reflecting a 10% year-on-year growth. Total revenue for the quarter was ₹3,856 crore, marking a 7% increase.

EBITDA came in at ₹787 crore, up 16% from the previous year.
Also read: GAIL Q3 Results: Stock rises despite missing estimates on EBITDA, margin frontLast year’s net profit was significantly boosted by the gains from the BFI divestment and Bicara stake sale. Without these exceptional items, Q3 FY24 had a marginal loss.

In comparison, Biocon reported a profit before tax and exceptional items of ₹138 crore in Q3 FY25, demonstrating a notable improvement in underlying profitability.

Sequentially, all three business segments reported growth. The generics segment grew by 10%, research services increased by 6%, and biosimilars rose by 5%.

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings announcement.